VIR BIOTECHNOLOGY, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OFWarrant Agreement • November 10th, 2020 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • New York
THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between Vir Biotechnology, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having a corporate trust office in [●], as warrant agent (the “Warrant Agent”).
Vir Biotechnology, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • July 6th, 2020 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • New York
Vir Biotechnology, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [ ● ] shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”, and such shares the “Firm Shares”) and, at the election of the Underwriters, up to [ ● ] additional shares (the “Optional Shares”) of Common Stock (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
VIR BIOTECHNOLOGY, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OFWarrant Agreement • November 10th, 2020 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • New York
THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [●], between Vir Biotechnology, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having a corporate trust office in [●], as warrant agent (the “Warrant Agent”).
VIR BIOTECHNOLOGY, INC. COMMON STOCK SALES AGREEMENTSales Agreement • November 3rd, 2023 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • New York
Vir Biotechnology, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
INDEMNITY AGREEMENTIndemnity Agreement • September 3rd, 2019 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of [ ], 20[ ], is made by and between VIR BIOTECHNOLOGY, INC., a Delaware corporation (the “Company”), and [ ] (“Indemnitee”). This Agreement terminates any and all previous indemnification agreements entered into by and between the Company and the Indemnitee.
LEASE AGREEMENTLease Agreement • September 3rd, 2019 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances)
THIS LEASE AGREEMENT (this “Lease”) is made this 30th day of March, 2017, between ARE-SAN FRANCISCO NO. 43, LLC, a Delaware limited liability company (“Landlord”), and VIR BIOTECHNOLOGY, INC., a Delaware corporation (“Tenant”).
VIR BIOTECHNOLOGY, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT November 29, 2017Investors’ Rights Agreement • September 3rd, 2019 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of November 29, 2017, by and among Vir Biotechnology, Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
LEASE THE EXCHANGE KRE EXCHANGE OWNER LLC a Delaware limited liability company as Landlord, and VIR BIOTECHNOLOGY, INC., a Delaware corporation As Tenant. 1800 Owens Street, San Francisco, California North Tower Floors 8, 9, 10, 11 and 12Lease • February 28th, 2022 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • California
This Lease (the “Lease”), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the “Summary”), below, is made by and between KRE EXCHANGE OWNER LLC, a Delaware limited liability company (“Landlord”), and VIR BIOTECHNOLOGY, INC., a Delaware corporation (“Tenant”).
August 27, 2019 Phil Pang, MD, PhD Dear Phil,Letter Agreement • September 3rd, 2019 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • California
This letter agreement (the “Agreement”) sets forth the terms and conditions of your continued employment with Vir Biotechnology, Inc. (“VirBio” or the “Company”). This Agreement supersedes and replaces all prior written employment agreements, offer letters, or oral promises regarding the subject matter herein, including, but not limited to, your initial December 5, 2016 offer letter agreement with the Company.
AGREEMENT AND PLAN OF MERGER dated as of January 2, 2018 by and among VIR BIOTECHNOLOGY, INC., VIR MERGER SUB, INC., AGENOVIR CORPORATION, and DR. STEPHEN R. QUAKE (solely in his capacity as Equityholders Representative)Agreement and Plan of Merger • September 3rd, 2019 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made and entered into as of January 2, 2018 by and among Vir Biotechnology, Inc., a Delaware corporation (“Parent”), Vir Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“Merger Sub”), Agenovir Corporation, a Delaware corporation (the “Company”), and Dr. Stephen R. Quake, solely in his capacity as the Equityholders Representative hereunder (each, a “Party” and collectively the “Parties”).
STOCK PURCHASE AGREEMENTStock Purchase Agreement • May 6th, 2021 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • Delaware
This Stock Purchase Agreement (“Agreement”) is entered into as of February 14, 2021 (the “Execution Date”), by and between Glaxo Group Limited, a private limited liability company incorporated under the laws of England and Wales having an office at 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom (“GSK”), and Vir Biotechnology, Inc. a Delaware corporation having an office at 499 Illinois Street, Suite 500, San Francisco, CA 94158 (“Vir”). The capitalized terms used herein and not otherwise defined have the meanings given to them in Appendix 1.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 3rd, 2019 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • New York
THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”) is made and entered into as of August 22, 2017, by and among: VIR BIOTECHNOLOGY, INC., a Delaware corporation (“Purchaser”); HUMABS BIOMED SA, a Swiss corporation limited by shares (the “Company”); the shareholders of the Company set forth on the signature pages hereto (each a “Shareholder” and, collectively, the “Shareholders”); the option holders of the Company set forth on the signature pages hereto (each an “Optionholder” and collectively, the “Optionholders”; each Shareholder and each Optionholder is also referred to herein as a “Securityholder” and any combination of Shareholders and Optionholders are also referred to herein as the “Securityholders”) and Fortis Advisors LLC, a Delaware limited liability company solely in its capacity as the Representative (the “Representative”). Capitalized terms used in this Agreement are defined in Exhibit A.
VIR BIOTECHNOLOGY, INC. INCENTIVE STOCK OPTION GRANT NOTICE AND AGREEMENTRofr Agreement • September 3rd, 2019 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • Delaware
Vir Biotechnology, Inc. (the “Company”), pursuant to its 2016 Equity Incentive Plan (the “Plan”), hereby grants to Participant an Option to purchase the number of shares of the Company’s Common Stock (referred to herein as “Shares”) set forth below. This Option is subject to all of the terms and conditions as set forth herein and in the Incentive Stock Option Agreement attached hereto as Exhibit A (the “Agreement”) and the Plan, each of which is incorporated herein by reference. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Incentive Stock Option Grant Notice (“Grant Notice”) and the Agreement.
FIRST AMENDMENT TO LEASELease • September 3rd, 2019 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances)
THIS FIRST AMENDMENT TO LEASE (this “First Amendment”) is made as of April 10, 2019, by and between ARE-SAN FRANCISCO NO. 43, LLC, a Delaware limited liability company (“Landlord”), and VIR BIOTECHNOLOGY, INC., a Delaware corporation (“Tenant”).
AMENDMENT TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • September 3rd, 2019 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances)
This AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this “Amendment”), entered into as of 17th May, 2019 (the “Amendment Date”), and effective as of the Effective Date, is made and entered into by and between The Rockefeller University, a New York not-for-profit education corporation, with a principal place of business at 1230 York Avenue, New York, NY 10065 (“Rockefeller”, also referred to herein as “Licensor”) and Vir Biotechnology, Inc. a Delaware corporation, with a principal place of business at 499 Illinois Street, Suite 500, San Francisco, CA 94158 (referred to herein as “Licensee”).
Vir Biotechnology, Inc. Portland, OR 97239Letter Agreement • September 3rd, 2019 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • Delaware
This letter agreement (the “Agreement”) is to confirm that in connection with the closing of the acquisition of TomegaVax by Vir Biotechnology, Inc. (the “Company”) pursuant to that certain Merger Agreement, dated as of the date hereof, by and among the Company, Vir Merger Sub 1, Inc., Vir Merger Sub 2, Inc., TomegaVax , the Stockholders and Klaus Früh as the Stockholders Representative thereunder (the “Merger Agreement”), and on or about the date hereof and for other good and valuable consideration, the adequacy and sufficiency of which is hereby acknowledged, the Company hereby makes the following covenants to each Stockholder:
VIR BIOTECHNOLOGY, INC. COMMON STOCK ISSUANCE AGREEMENTCommon Stock Issuance Agreement • September 3rd, 2019 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS COMMON STOCK ISSUANCE AGREEMENT (the “Agreement”) is effective as of the 16th day of October, 2017 (the “Effective Date”), by and among VIR BIOTECHNOLOGY, INC., a Delaware corporation (the “Company”), and ALNYLAM PHARMACEUTICALS, INC., a Delaware corporation (“Purchaser” and, together with Company, the “Parties”). Capitalized terms used and not otherwise defined herein shall have the meaning ascribed thereto in the License Agreement (as defined below).
DEVELOPMENT AND MANUFACTURING COLLABORATION AGREEMENT by and between VIR BIOTECHNOLOGY, INC. and WUXI BIOLOGICS (HONG KONG) LIMITED 25 February 2020Development and Manufacturing Collaboration Agreement • July 6th, 2020 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • New York
This Development and Manufacturing Collaboration Agreement (this “Agreement”) is made effective as of February 25, 2020 (the “Effective Date”) by and between Vir Biotechnology, Inc., a Delaware corporation having an address at 499 Illinois Street, San Francisco, CA 94158 USA (“Vir”), and WuXi Biologics (Hong Kong) Limited., a Hong Kong corporation with a place of business at Building 1, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, China 200131 (“WuXi”). Vir and WuXi are each hereafter referred to individually as a “Party” and together as the “Parties.”
AMENDMENT INFORMATION Agreement to be Amended: Grant agreement between the Bill & Melinda Gates Foundation and Vir Biotechnology, Inc. effective March 16, 2018 and bearing Investment ID OPP1182112 Amendment Purpose: Reporting & Payment Schedule Change...Vir Biotechnology, Inc. • March 26th, 2020 • Biological products, (no disgnostic substances)
THIS AMENDMENT amends, and is made part of, the above-referenced Agreement and is effective as of the date of this email. Capitalized terms not defined in this Amendment will have the meaning provided in the Agreement. Except as modified by this Amendment, all other terms and conditions of the Agreement remain in full force and effect. In the event of a conflict between the Agreement and this Amendment, the terms of this Amendment will prevail.
AMENDMENT INFORMATION Agreement to be Amended: Grant agreement between the Bill & Melinda Gates Foundation and Vir Biotechnology Inc effective March 16, 2018, as amended, and bearing Investment ID INV-009475/OPP1182112 Amendment Purpose: No Cost...Vir Biotechnology, Inc. • February 28th, 2022 • Biological products, (no disgnostic substances)
THIS AMENDMENT amends, and is made part of, the above-referenced Agreement and is effective as of the date of this email. Capitalized terms not defined in this Amendment will have the meaning provided in the Agreement. Except as modified by this Amendment, all other terms and conditions of the Agreement remain in full force and effect. In the event of a conflict between the Agreement and this Amendment, the terms of this Amendment will prevail.
AMENDMENT NO. 1 TO THE COMMON STOCK ISSUANCE AGREEMENTCommon Stock Issuance Agreement • March 26th, 2020 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • Delaware
This Amendment No. 1 to the Common Stock Issuance Agreement (“Amendment”) is made and entered into, effective as of December 17, 2019 (“Amendment Effective Date”), by and between Vir Biotechnology, Inc., a Delaware corporation with offices at with an office at 499 Illinois Street, San Francisco, California 94158 (“Vir”), and Alnylam Pharmaceuticals, Inc., a Delaware corporation located at 300 Third Street, Cambridge, Massachusetts 02142 (“Alnylam”). Each of Vir and Alnylam are referred to in this Amendment as a “Party” and together, the “Parties”.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.Certain • February 25th, 2021 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • New York
RE: Collaboration and License Agreement by and among Vir Biotechnology, Inc. and Alnylam Pharmaceuticals, Inc. effective October 16, 2017, as amended by letter agreement dated November 13, 2018, Amendment No. 1 to the Collaboration and License Agreement effective December 17, 2019, Amendment No. 2 to the Collaboration and License Agreement effective March 3, 2020 (“Amendment No. 2”) and Amendment No. 3 to the Collaboration and License Agreement effective April 1, 2020 (“Amendment No. 3”) (the “Collaboration Agreement”).
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT VIR BIOTECHNOLOGY, INC. TREATS AS PRIVATE OR CONFIDENTIAL.Letter Agreement • February 28th, 2022 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • Washington
This amended and restated letter agreement (including all appendices hereto, this “Letter Agreement”) is entered into as of January 12, 2022 by and between the Bill & Melinda Gates Foundation (the “Foundation”), a Washington charitable trust that is a tax-exempt private foundation, and Vir Biotechnology, Inc., a Delaware corporation (the “Company”) and is effective on the Amendment Effective Date (as defined below). This Letter Agreement amends and restates in its entirety the letter agreement entered into as of December 23, 2016 (“Effective Date”) by and between the Foundation and the Company (the “Prior Agreement”), in connection with the investment by the Foundation of twenty million dollars ($20,000,000.00) in the Company through the purchase of (i) ten million dollars ($10,000,000.00) of shares of Series A-1 Preferred Stock, par value $0.0001, of the Company (the “Series A-1 Shares”) at a purchase price of [***] per share and (ii) ten million dollars ($10,000,000.00) of shares of
SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • February 25th, 2021 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances)
This SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this “Amendment 2”), entered into as of September 28th, 2020 (the “Amendment Date”), and effective as of the Effective Date, is made and entered into by and between The Rockefeller University, a New York not-for-profit education corporation, with a principal place of business at 1230 York Avenue, New York, NY 10065 (“Rockefeller”, also referred to herein as “Licensor”) and Vir Biotechnology, Inc. a Delaware corporation, with a principal place of business at 499 Illinois Street, Suite 500, San Francisco, CA 94158 (referred to herein as “Licensee”).
AMENDMENT INFORMATION Agreement to be Amended: Grant agreement between the Bill & Melinda Gates Foundation and Vir Biotechnology, Inc. effective March 16, 2018, as amended, and bearing Investment ID OPP1182112 Amendment Purpose: Reporting and Payment...Vir Biotechnology, Inc. • March 26th, 2020 • Biological products, (no disgnostic substances)
THIS AMENDMENT amends, and is made part of, the above-referenced Agreement and is effective as of the date of this email. Capitalized terms not defined in this Amendment will have the meaning provided in the Agreement. Except as modified by this Amendment, all other terms and conditions of the Agreement remain in full force and effect. In the event of a conflict between the Agreement and this Amendment, the terms of this Amendment will prevail.
ASSIGNMENT AND NOVATION AGREEMENTAssignment and Novation Agreement • August 7th, 2020 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS ASSIGNMENT AND NOVATION AGREEMENT (this “Assignment Agreement”) is made as of July 31, 2020 (“Assignment Date”), by and among Vir Biotechnology, Inc., a Delaware corporation having a principal place of business at 499 Illinois Street, Suite 500, San Francisco, CA 94158 U.S.A (“Assignor”), GlaxoSmithKline Trading Services Limited, a company registered in Ireland under company number 406466 having a principal place of business at 980 Great West Road, Brentford, Middlesex, TW8 9GS, England, (“Assignee”), and Samsung BioLogics Co., Ltd., a Republic of Korean company having a principal place of business at 300, Songdo bio-daero, Yeonsu-gu, Incheon 21987 Republic of Korea (“Supplier”). Assignor, Assignee and Supplier are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
ContractSub-Licence and Collaboration Agreement • September 3rd, 2019 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • New York
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
AMENDMENT NO. 2 TO THE COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • March 26th, 2020 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • New York
This Amendment No. 2 to the Collaboration and License Agreement (“Amendment”) is made and entered into, effective as of March 3, 2020 (“Amendment No. 2 Effective Date”), by and between Vir Biotechnology, Inc., a Delaware corporation with offices at with an office at 499 Illinois Street, San Francisco, California 94158 (“Vir”), and Alnylam Pharmaceuticals, Inc., a Delaware corporation located at 300 Third Street, Cambridge, Massachusetts 02142 (“Alnylam”). Each of Vir and Alnylam are referred to in this Amendment as a “Party” and together, the “Parties”.
AMENDMENT NO. 3 TO THE COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • June 23rd, 2020 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • New York
THIS AMENDMENT NO. 3 TO THE COLLABORATION AND LICENSE AGREEMENT (“Amendment”) is made and entered into, effective as of April 1, 2020 (“Amendment No. 3 Effective Date”), by and between Vir Biotechnology, Inc., a Delaware corporation with offices at with an office at 499 Illinois Street, San Francisco, California 94158 (“Vir”), and Alnylam Pharmaceuticals, Inc., a Delaware corporation located at 675 West Kendall Street – Henri A. Termeer Square, Cambridge, Massachusetts 02142 (“Alnylam”). Each of Vir and Alnylam are referred to in this Amendment as a “Party” and together, the “Parties”.
Preliminary Collaboration AgreementPreliminary Collaboration Agreement • May 6th, 2021 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances)
This Preliminary Collaboration Agreement (this “Preliminary Collaboration Agreement” or “PCA”) is entered into as of February 14, 2021 (the “PCA Execution Date”), by and between Glaxo Wellcome UK Limited, (“GSK”) and Vir Biotechnology, Inc. (“VIR”). VIR and GSK may be referred to individually as a “Party” and collectively as the “Parties.” Reference is made to that certain Definitive Collaboration Agreement between GSK and VIR dated June 9, 2020 (the “Existing Collaboration Agreement”). This PCA sets forth the key terms upon which the Parties would expand the collaboration to include (a) an antibody program directed towards influenza, (b) functional genomics approaches to Respiratory Viral Diseases (as defined below), and (c) antibody programs directed towards additional pathogens, each, as further described below (collectively, the “Collaboration”). It is anticipated that following the PCA Execution Date, the Parties will enter into a definitive agreement to include more detailed term
ContractVir Biotechnology, Inc. • August 7th, 2019 • Biological products, (no disgnostic substances)
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED.
LETTER OF INTENT BETWEEN Vir Biotechnology, Inc. AND WUXI BIOLOGICS (HONG KONG) LIMITEDVir Biotechnology, Inc. • June 23rd, 2020 • Biological products, (no disgnostic substances)
This Letter of Intent (“LOI”) confirms the recent discussions between Vir Biotechnology, Inc. (“Vir”) and WuXi Biologics (Hong Kong) Limited (“WuXi Biologics”) whereby Vir reserves some capacity in WuXi Biologics’s bulk drug substance facility referred to as Manufacturing #2 (the “Capacity Reservation”) and retains WuXi Biologics to perform certain development and/or manufacturing services (the “Services”) regarding Vir’s VIR-7831 SARS-Cov-2 mAb (also referred to as WBP2275 within WuXi Biologics) (the “Initial Product”) or any backup SARS CoV-2 mAb product that Vir may specify from time to time (collectively, the Initial Product and any backup product specified by Vir, the “Product”).
PATENT LICENSE AGREEMENTPatent License Agreement • June 19th, 2020 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • New York
This PATENT LICENSE AGREEMENT (this “Agreement”), effective as of March 25, 2020 (the “Effective Date”), is made by and between Vir Biotechnology, Inc., a Delaware corporation (“VirBio”), having a principal place of business at 499 Illinois St, San Francisco, CA 94158, and Xencor, Inc., a Delaware corporation (“Xencor”), having a principal place of business at 111 West Lemon Avenue, Monrovia, California 91016. VirBio and Xencor may each be referred to herein individually as a “Party” or collectively as the “Parties”.
OPP1187970, Amendment 1 to Vir BiotechnologyVir Biotechnology, Inc. • March 26th, 2020 • Biological products, (no disgnostic substances)
THIS AMENDMENT amends, and is made part of, the above-referenced Agreement and is effective as of the date of this email. Capitalized terms not defined in this Amendment will have the meaning provided in the Agreement. Except as modified by this Amendment, all other terms and conditions of the Agreement remain in full force and effect. In the event of a conflict between the Agreement and this Amendment, the terms of this Amendment will prevail.
ContractDefinitive Collaboration Agreement • August 5th, 2021 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • Delaware
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT VIR BIOTECHNOLOGY, INC. TREATS AS PRIVATE OR CONFIDENTIAL.
